Skip to main content

Shopping Cart

You're getting the VIP treatment!

Item(s) unavailable for purchase
Please review your cart. You can remove the unavailable item(s) now or we'll automatically remove it at Checkout.
itemsitem
itemsitem

Recommended For You

Loading...
  • Access to Non-Summary Clinical Trial Data for Research Purposes Under EU Law

    by Daria Kim ...
    Series series Law and Criminology (R0)
    This book draws a unique perspective on the regulation of access to clinical trial data as a case on research and knowledge externalities. Notwithstanding numerous potential benefits for medical research and public health, many jurisdictions have struggled to ensure access to clinical trial data, even at the level of the trial results. Pro-access policy initiatives have been strongly opposed by ... Read more

    $154.99 CAD

  • Contemporary Issues in Pharmaceutical Patent Law

    Setting the Framework and Exploring Policy Options

    Edited by Bryan Mercurio, Daria Kim ...
    Series series Routledge Research in Intellectual Property
    This collection reflects on contemporary and contentious issues in international rulemaking in regards to pharmaceutical patent law. With chapters from both well-established and rising scholars, the collection contributes to the understanding of the regulatory framework governing pharmaceutical patents as an integrated discipline through the assessment of relevant laws, trends and policy options. ... Read more

    $97.99 CAD

People who read these also enjoyed

  • Bad Pharma

    How Drug Companies Mislead Doctors and Harm Patients

    by Ben Goldacre ...
    We all feel uncomfortable about the role of profit in healthcare, we all have a vague notion that the global $600bn pharmaceutical industry is somehow evil and untrustworthy, but that sense rarely goes beyond a flaky, undifferentiated new age worldview. Bad Pharma puts real flesh on those bones, revealing the rigged evidence used by drug companies. Bad information means bad treatment decisions, ... Read more

    $13.99 CAD

  • Healthcare Management

    A comprehensive, research-based introduction to healthcare management, covering healthcare systems, services, organisations and management. ... Read more

    $64.99 CAD

  • Doctors in Denial

    Why Big Pharma and the Canadian medical profession are too close for comfort

    by Joel Lexchin ...
    Doctors in Denial examines the relationship between the Canadian medical profession and the pharmaceutical industry, and explains how doctors have become dependents of the drug companies instead of champions of patients' health. Big Pharma plays a role in every aspect of doctors' work. These giant, wealthy multinationals influence how medical students are trained and receive information, how ... Read more

    $16.99 CAD

  • Private Profits versus Public Policy

    The Pharmaceutical Industry and the Canadian State

    by Joel Lexchin ...
    The widespread condemnation of drastic price increases on life-saving drugs highlights our growing dependency on and vulnerability to international pharmaceutical conglomerates. However, aren’t the interests of the public supposed to supersede the pursuit of private profit?In his new work, Private Profits versus Public Policy, Joel Lexchin addresses this question as he examines how public policy ... Read more

    $35.99 CAD

  • Oxford Handbook of Public Health Practice

    Series series Oxford Medical Handbooks
    Fully revised and updated for the fourth edition, the award-winning Oxford Handbook of Public Health Practice remains the first resort for practitioners in the field. Structured into practical sections addressed towards professional competencies and translating evidence into policy, this Handbook provides concise summaries and covers real issues from across the globe, providing a world of ... Read more

    $21.99 CAD

  • Pharmaceutical Market Access in Developed Markets

    Market access is the process by which a pharmaceutical company gets its product available on the market after having obtained a marketing authorization from a regulatory agency and by which the product becomes available for all patients for whom it is indicated as per its marketing authorization.It covers a group of activities intended to provide access to the appropriate medicine for the ... Read more

    $14.99 CAD or Free with Kobo Plus

  • When Experiments Travel

    Clinical Trials and the Global Search for Human Subjects

    The phenomenal growth of global pharmaceutical sales and the quest for innovation are driving an unprecedented search for human test subjects, particularly in middle- and low-income countries. Our hope for medical progress increasingly depends on the willingness of the world's poor to participate in clinical drug trials. While these experiments often provide those in need with vital and previously ... Read more

    $17.99 CAD or Free with Kobo Plus

  • Where to from Here?

    Keeping Medicare Sustainable

    Series Book 161 - Queen's Policy Studies Series
    Universal healthcare, perhaps the most distinguishing feature of Canada's public policy, is under fire, criticized for its heavy expense and questionable sustainability. In Where to From Here?: Keeping Medicare Sustainable, Stephen Duckett defends Canadian Medicare, addressing key concerns and refuting criticism, while also acknowledging flaws in the system and room for improvement.Duckett argues ... Read more

    $32.99 CAD

  • The Commercial Determinants of Health

    An accessible multidisciplinary overview for anyone seeking to understand the commercial determinants of health Our health is largely shaped by the world around us—by the conditions in which we grow, work, and live. These conditions include the commercial determinants of health, the private sector activities which influence our physical and social environments, our available evidence and solutions ... Read more

    $68.39 CAD

  • Human Subjects Research Regulation

    Perspectives on the Future

    Series series Basic Bioethics
    Experts from different disciplines offer novel ideas for improving research oversight and protection of human subjects.The current framework for the regulation of human subjects research emerged largely in reaction to the horrors of Nazi human experimentation, revealed at the Nuremburg trials, and the Tuskegee syphilis study, conducted by U.S. government researchers from 1932 to 1972. This ... Read more

    $36.79 CAD